EGFR and cancer: Antagonism of the epidermal growth factor receptor (EGFR) in cancer cells disrupts normal epithelial endorsement and succession, limiting normal cell transformation into persistent and metastatic cancer cells via dysplasia to high-grade prostatic intraepithelial neoplasia (HGPIN) [6-8].